He Huang

State Key Laboratory Of Oncology In South China, Guangdong Key Laboratory Of Nasopharyngeal Carcinoma Diagnosis And Therapy, 651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025.

Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025.

Journal: Experimental hematology & oncology

Published: April 27, 2026

An inflammation-integrated prognostic nomogram for advanced-stage extranodal NK/T-cell lymphoma: a multicenter retrospective study.

An inflammation-integrated prognostic nomogram for advanced-stage extranodal NK/T-cell lymphoma: a multicenter retrospective study.

Journal: Annals of hematology

Published: October 22, 2025

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.

Journal: Blood advances

Published: October 22, 2025

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.

Journal: Blood advances

Published: October 22, 2025

Low prognostic nutritional index predicts poor outcome in newly diagnosed angioimmunoblastic T-cell lymphoma.

Low prognostic nutritional index predicts poor outcome in newly diagnosed angioimmunoblastic T-cell lymphoma.

Journal: Frontiers in nutrition

Published: May 04, 2025

A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma.

A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma.

Journal: Journal of hematology & oncology

Published: February 17, 2025

Comprehensive analyses reveal the promising value of gasdermins as prognostic biomarkers and immunotherapeutic targets in head and neck squamous cell carcinoma.

Comprehensive analyses reveal the promising value of gasdermins as prognostic biomarkers and immunotherapeutic targets in head and neck squamous cell carcinoma.

Journal: Heliyon

Published: December 05, 2024

Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress.

Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress.

Journal: Journal of hematology & oncology

Published: October 16, 2024

A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter study.

A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter study.

Journal: Annals of hematology

Published: September 04, 2024

Magnetic Resonance Imaging and [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Guided Therapy Improves Survival in Upper Aerodigestive Tract NK/T-Cell Lymphoma, Nasal Type: A Prospective Cohort Study.

Magnetic Resonance Imaging and [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Guided Therapy Improves Survival in Upper Aerodigestive Tract NK/T-Cell Lymphoma, Nasal Type: A Prospective Cohort Study.

Journal: Head & neck

Published: September 01, 2024

Risk stratification based on changes in the standard maximal uptake value on PET/CT and the plasma Epstein‒Barr virus (EBV) DNA status after two cycles of chemotherapy for extranodal NK-/T-cell lymphoma.

Risk stratification based on changes in the standard maximal uptake value on PET/CT and the plasma Epstein‒Barr virus (EBV) DNA status after two cycles of chemotherapy for extranodal NK-/T-cell lymphoma.

Journal: Annals of hematology

Published: July 24, 2024

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting.

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting.

Journal: Experimental hematology & oncology

Published: February 08, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026